Previous 10 | Next 10 |
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notic...
2024-04-19 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
2024-04-17 09:19:37 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for Allarity Therapeutics Read the full article on Seeking Alpha ...
Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14...
2024-04-15 08:41:18 ET More on premarket gainers & stock Carvana, Vroom, BuzzFeed, Encore Wire - Getting Paid To Take Risks With Courage & Conviction Investing U.S. Energy Corp. (USEG) Q4 2023 Earnings Call Transcript Cutera, Inc. (CUTR) Q4 2023 Earnings Call...
Allarity Therapeutics Inc (NASDAQ: ALLR) is one of today's top gainers. The company's shares have moved 20.87% on the day to $2.78. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics gen...
A look at the top 10 most actives in the United States Beneficient (BENF) rose 44.7% to $0.1 on volume of 79,601,246 shares PaxMedica Inc. (PXMD) rose 123.0% to $0.9183 on volume of 54,446,384 shares NextPlat Corp (NXPL) rose 40.0% to $2.1 on volume of 30,284,097 shares Direxion Daily S...
2024-04-12 09:01:35 ET More on premarket gainers & stock Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Globe Life Inc. (GL) Q4 2023 Earnings Call Transcript Alterity Therapeutics receives A$3.9M research & development tax incentive refund ...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 26.7% to $0.717 on volume of 293,193,103 shares PROSHARES TRUST (SQQQ) fell 4.6% to $10.4 on volume of 158,399,098 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.4% to $3.21 on volume o...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 96.2% to $0.0785 on volume of 428,216,483 shares Mobile Global Esports Inc. (MGAM) rose 77.8% to $0.216 on volume of 139,335,972 shares PROSHARES TRUST (SQQQ) fell 1.2% to $10.61 on volume of 128,866...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its F...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Compa...